Hypothalamic substance P release: Attenuated angiotensin responses in mRen2(27) transgenic rats

Hypertension

Volumn 29, Issue 1 II, 1997, Pages 510-513

  Diz, Debra I ^a   Falgui, Burt ^a   Bosch, Susan M ^a   Westwood, Brian M ^a   Kent, Jessica ^a   Ganten, Detlev ^b   Ferrario, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

angiotensin peptides; hypertension; hypothalamus; renin transgenic rat; substance P

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN DERIVATIVE; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; HYPERTENSION; HYPOTHALAMUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THALAMUS MIDLINE NUCLEUS; TRANSGENIC ANIMAL; VASOPRESSIN RELEASE;

EID: 0031036412     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.29.1.510     Document Type: Article

References (27)

1. Senanayake PD, Moriguchi A, Kumagai H, Ganten D, Ferrario CM, Brosnihan KB. Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. Peptides. 1994;15:919-926.
2. Moriguchi A, Ferrario CM, Brosnihan KB, Ganten D, Morris M. Differential regulation of central vasopressin in transgenic rats harboring the mouse Ren-2 gene. Am J Physiol . 1994;267:R786-R791.
3. Li P, Morris M, Diz DI, Ferrario CM, Ganten D, Callahan MF. Role of paraventricular angiotensin AT-1 receptors in salt sensitive hypertension in mRen-2 transgenic rats. Am J Physiol. 1996;270: R1178-R1181.
4. Diz DI, Moriguchi A, Bosch SM, Ganten D, Ferrario CM. Angiotensin receptor regulation in paraventricular nucleus (PVN) differs in SHR and transgenic (mREN2) 27 rats. Am J Hypertens. 1994;7:30A. Abstract.
5. Tallant EA, Ganten D, Ferrario CM. Attenuated responses to angiotensin II in vascular smooth muscle cells from transgenic (mREN2) 27 rats. Am J Hypertens. 1994;7:1359. Abstract.
6. Weiss RB, Ganten D, Ferrario CM, Tallant EA. Reduced response to Ang II in astrocytes isolated from neonatal brain of (mREN2)27 transgenic rats. Hypertension. 1995;25:1410. Abstract.
7. Diz DI, Bosch SM, Moriguchi A, Ganten D, Ferrario CM. Converting enzyme inhibition lowers angiolensin II receptor density in medulla of transgenic (mREN2)27 rats. J Hypertens. 1994;12:S71. Abstract.
8. Barnes KL, Diz DI, Ferrario CM. Functional interactions between angiotensin II and substance P in the dorsal medulla. Hypertension. 1991;17:1121-1126.
9. Diz DI, Pirro N. Differential actions of angiotensin II and angiotensin-(1-7) on transmitter release. Hypertension. 1992;19(suppl II):II-41-II-48.
10. Perfumi M, Massi M, Epstein AN, DeCaro G. Neurokinin A is a specific and precocious inhibitor of water intake in neonatal rats. Peptides. 1990;11:339-344.
11. Massi M, Polidori C, Perfumi M, Gentili L, DeCaro G. Tachykinin receptor subtypes involved in the central effects of tachykinins on water and salt intake. Brain Res. 1991;26:155-160.
12. Massi M, Saija A, Polidori C, Perfumi M, Gentili L, Costa G, DeCaro G. The hypothalamic paraventricular nucleus is a site of action for the central effect of tachykinins on plasma vasopressin. Brain Res Bull. 1991;26:149-154.
13. Diz DI, Fantz DL, Benter IF, Bosch SM. Substance P antagonist blocks the cardiovascular effects of angiotension II in the rat nucleus tractus solitarii. Hypertension. 1995;25:1360. Abstract.
14. Perfumi M, Sajia A, Costa G, Massi M, Polidori C. Vasopressin release induced by intracranial injection of eledoisin is mediated by central angiotensin II. Pharmacol Res Commun. 1988;20:811-826.
15. Tallant EA, Jaiswal N, Diz DI, Ferrario CM. Human astrocytes contain two distinct angiotensin receptor subtypes. Hypertension. 1991;18:32-39.
16. Jaiswal N, Tallant EA, Diz DI, Khosla MC, Ferrario CM. Subtype 2 angiotensin receptors mediate prostaglandin synthesis in human astrocytes. Hypertension. 1991;17:1115-1120.
17. Freeman EJ, Ferrario CM, Tallant EA. Angiotensins differently activate phospholipase D in vascular smooth muscle cells from spontaneously hypertensive and Wistar-Kyoto rats. Am J Hypertens. 1995;8:1105-1111.
18. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-11-71 [Ang.-(1-7)] inhibits vascular smooth muscle cell growth. Hypertension. 1996;28:104-108.
19. Schiavone MT, Santos RAS, Brosnihan KB, Khosla MC, Ferrario CM. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiolensin-(1-7) heptapeptide. Proc Natl Acad Sci U S A. 1988;85:4095-4098.
20. Hoffman WE, Phillips MI. Independent receptors for pressor and drinking responses to central injections of angiotensin II and carbachol. Brain Res. 1977;124:305-315.
21. Hogarty DC, Speakman EA, Puig V, Phillips MI. The role of angiotensin, AT1 and AT2 receptors in the pressor; drinking and vasopressin responses to central angiotensin. Brain Res. 1992;586: 289-294.
22. Felix D, Khosla MC, Barnes KL, Imboden H, Montani B, Ferrario CM. Neurophysiological responses to angiotensin-(1-7). Hypertension. 1991;17:1111-1114.
23. Unger T, Becker H, Petty M, Demmert G, Schneider B, Ganten D, Lang RE. Differential effects of central angiotensin II and substance P on sympathetic nerve activity in conscious rats. Circ Res. 1985;56:563-575.
24. Yamaguchi K, Karakida T, Koike M, Hama H. Central effects of catecholamine antagonists on angiotensin-induced vasopressin secretion in conscious rats. Acta Endocrinol. 1988;118:82-88.
25. Kawabe H, Brosnihan KB, Diz DI, Ferrario CM. Role of brain dopamine in centrally evoked angiotensin II responses in conscious rats. Hypertension. 1986;8(suppl I):I-84-I-89.
26. Benarroch EE, Pirola CJ, Alvarez AL, Nahmod VE. Serotonergic and noradrenergic mechanisms involved in the cardiovascular effects of angiotensin II injected into the anterior hypothalamic preoptic region of rats. Neuropharmacology. 1981;20:9-13.
27. Chevillard C, Duchene N, Pasquier R, Alexandre JM. Relation of the centrally evoked pressor effect of angiotensin II to central noradrenaline in the rabbit. Eur J Pharmacol. 1979;58:203-206.